Barclays Reiterates Buy Rating for Guardant Health, Inc.
Barclays maintains a Buy rating on Guardant Health with a $150 price target, a 4.94% upside from the current price.
Key Points
- Barclays reiterated its Buy rating on Guardant Health, Inc. (GH) on June 24, 2026, with a price target of $150.
- Barclays's $150 price target implies 4.94% upside from Guardant Health, Inc.'s ($GH) current $142.94 share price.
- Shares of NasdaqGS:GH traded near $130.83 on Wednesday, with a market cap of approximately $17.08 billion.
- Guardant Health is a healthcare company specializing in precision oncology, headquartered in Palo Alto, California.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays has reiterated its Buy rating on Guardant Health, Inc. (NasdaqGS:GH) as of June 24, 2026. Analyst Luke Sergott set a price target of $150 for the precision oncology company, maintaining confidence in its growth potential.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Guardant Health, Inc. Stock Down 11.5%
Shares of Guardant Health traded near $130.83 on Wednesday. The company, which specializes in diagnostics and research, has a market cap of about $17.08 billion. Its forward P/E ratio is not meaningful as it isn't profitable, with an EPS of -$3.40. Guardant Health's stock has ranged from $40.35 to $135.00 over the past 52 weeks. The stock's 50-day moving average is $105.79, and its 200-day moving average is $93.91. Guardant Health maintains a strong liquidity position with a current ratio of 4.68 and a quick ratio of 4.25.
$GH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest earnings report, Guardant Health posted a revenue of approximately $1.08 billion, reflecting a growth of 48.3%. Despite this growth, the company recorded a net margin of -40.1%. The next earnings announcement is expected on July 29, 2026.
Insider Buying and Selling at Guardant Health, Inc.
Recent insider activity at Guardant Health includes planned sales by Tariq Musa and Myrtle Potter, who sold 1,951 and 1,556 shares respectively at an average price of $131.16 on June 22, 2026. Additionally, Roberto Mignone made several transactions, including both buying and selling 264 shares on various dates without a specified price.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained its Buy rating on Guardant Health with a $150 price target. Earlier in June, RBC Capital initiated coverage with a Buy rating and a $185 target, while Mizuho maintained a Buy rating with a $175 target. Goldman Sachs also initiated coverage with a Buy rating and a $165 target.
About Guardant Health
Guardant Health, Inc. is a healthcare company focused on precision oncology. It provides blood and tissue tests, as well as data sets, to advance cancer research and therapy development. The company offers various tests, including the Guardant360 CDx test and the Guardant Reveal test, which are designed to detect cancer at the molecular level. Headquartered in Palo Alto, California, Guardant Health employs about 2,490 people and is led by CEO Dr. Helmy Eltoukhy.
Bottom Line
Barclays' reiterated Buy rating on Guardant Health highlights ongoing confidence in the company's potential. Investors often track such analyst ratings as part of their decision-making process. As a reminder, these ratings reflect opinions at the time of publication and may not indicate future performance.
Get Guardant Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.